Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Will Acquire NimbleGen

June 25, 2007 | A version of this story appeared in Volume 85, Issue 26

Roche will purchase NimbleGen Systems for $273 million in an attempt to build its position in the genomics research market. Just last month, Roche completed a $155 million acquisition of the gene-sequencing technology company 454 Life Sciences. The Swiss drugmaker already had a strong foundation in polymerase chain reaction (PCR) technology and instrumentation. To this mix, NimbleGen brings high-density DNA microarray technology and related instruments and reagents. The global market for microarray systems is estimated at $600 million per year and grew 10% in 2006, according to Roche. Major competitors include Affymetrix, Agilent Technologies, and Illumina. Located in Madison, Wis., NimbleGen was founded in late 1999 with technology licensed from the University of Wisconsin. The company had started planning in March for a $75 million initial stock offering. Its 140 employees and operations at three sites—Madison; Reykjavik, Iceland; and Waldkraiburg, Germany—will become part of Roche Applied Science, a business in Roche's diagnostics division. Pending shareholder approval, the deal is expected to close in the third quarter.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.